gemtuzumab ozogamicin,Glasdegib
pfizer,ucb pharmaceuticals
['aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'gemtuzumab', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)']
 gemtuzumab ozogamicin plus intensive chemotherapy impacts on the level of post-consolidation measurable residual disease (mrd) of favorable/intermediate aml, recruited to the gimema aml1819 protocol
venditti a et al. 
Gruppo Italiano Malattie EMatologiche dell'Adulto